Clinical Trials

132 enrolled

Breast Neoplasms

NCT02525211 2026-04-21

Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment

Phase 3 Terminated

59 enrolled

Breast Neoplasms

NCT03927027 2026-04-21

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

534 enrolled

Breast Neoplasms

NCT04732598 2026-04-21

AMBITION

281 enrolled

Breast Neoplasms

NCT04964934 2026-04-21

SERENA-6

315 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05696626 2026-04-21

ELAINEIII

500 enrolled

Breast Neoplasms

NCT06058377 2026-04-21

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT07173751 2026-04-21

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

558 enrolled

Breast Neoplasms

NCT07541079 2026-04-21

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

300 enrolled

Breast Neoplasms

NCT04862663 2026-04-20

CAPItello-292

895 enrolled

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT05132582 2026-04-20

HER2CLIMB-05

654 enrolled

Breast Neoplasms

NCT06382142 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

418 enrolled

Triple Negative Breast Neoplasms

NCT06841354 2026-04-20

TroFuse-011

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT05780567 2026-04-17

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

1,946 enrolled

Breast Neoplasms

NCT06195709 2026-04-17

ECLECTIC

300 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06343948 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

383 enrolled

HR+HER2- Breast Cancer

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07174336 2026-04-17

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07205822 2026-04-17

TB06

100 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07400523 2026-04-17

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

446 enrolled

Breast Neoplasms

NCT04085276 2026-04-16

TORCHLIGHT

531 enrolled

Triple Negative Breast Neoplasms

NCT04421963 2026-04-16

ROSY-O

185 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Breast Neoplasms

NCT07060807 2026-04-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

400 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07085767 2026-04-16

OPERA-02

1,000 enrolled

Breast Neoplasms

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

364 enrolled

Triple Negative Breast Neoplasms

NCT04852887 2026-04-15

DEBRA

1,670 enrolled

Breast Neoplasms

NCT02311959 2026-04-14

MAPAM-01

450 enrolled

Breast Neoplasms, Carcinoma in Situ

NCT03488693 2026-04-14

TAILOR RT

2,140 enrolled

Breast Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT06380751 2026-04-14

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT07528716 2026-04-14

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

280 enrolled

Breast Neoplasms

NCT00310180 2026-04-13

TAILORx

10,273 enrolled 14 charts

Breast Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT02954874 2026-04-13

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04650581 2026-04-13

FINER

250 enrolled 13 charts

Breast Neoplasms

NCT05417516 2026-04-13

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

910 enrolled

Breast Neoplasm Female

NCT05774951 2026-04-13

CAMBRIA-1

4,300 enrolled

Breast Neoplasms

NCT06393374 2026-04-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

1,530 enrolled

Triple Negative Breast Neoplasms

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

1,978 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT03820830 2026-04-09

POLAR

405 enrolled

Breast Cancer Recurrent

NCT05038735 2026-04-08

EPIK-B5

234 enrolled

Breast Neoplasms

NCT05375461 2026-04-08

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

293 enrolled

HR-positive,HER2-negative in Advanced Breast Cancer

NCT05950945 2026-04-08

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

250 enrolled

Breast Neoplasms

NCT06764186 2026-04-08

CAPItana

101 enrolled

Breast Neoplasms

NCT07441460 2026-04-08

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

1,800 enrolled

Resectable HER2-positive Breast Cancer

NCT07518173 2026-04-08

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

596 enrolled

HER2-positive Breast Cancer

NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer